Register for our free email digests:
Merck & Co. Inc.
www.merck.com
Latest From Merck & Co. Inc.
ASCO 2020: Roche Highlights TIGIT As Tecentriq Bags Another Approval
The Swiss major focused almost exclusively on the benefits of the combination of Tecentriq and its TIGIT inhibitor tiragolumab at ASCO but also celebrated the approval of a Tecentriq/Avastin combo for hepatocellular carcinoma.
Is Pharma Too Introspective To Be Truly Innovative?
The pharmaceutical industry is more diverse today in terms of nationality and culture. However, there is still a lack of other types of diversity, which blocks the proactive inclusion of different perspectives. Raafi-Karim Alidina, a consultant with global diversity and inclusion consultancy Frost Included and the co-author of Building An Inclusive Organisation, shares his thoughts.
Bavencio’s Survival Benefit Confirmed In Front-Line Maintenance Therapy For Advanced Urothelial Cancer
Further details of Merck KGaA/Pfizer-funded JAVELIN Bladder 100 study presented at this year’s ASCO confirm avelumab’s survival benefit when used as front-line maintenance therapy in patients with advanced urothelial cancer that has not progressed following initial chemotherapy.
Merck's Keytruda Doubled PFS In Some Colorectal Cancer Patients In ASCO Late-Breaker
Pembrolizumab should be considered the new standard of care as first-line therapy in patients with microsatellite instability high (MSI-H) metastatic colorectal cancer, KEYNOTE-177 investigator André said.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
- Therapeutic Areas
- Cardiovascular
- Gynecological, Urological
- Infectious & Viral Diseases
- Inflammation
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Ophthalmic
- Respiratory, Pulmonary
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Company Type
- Big Pharma
- Parent & Subsidiaries
-
Merck & Co. Inc.
- Abello SA
- Abmaxis Inc.
- Afferent Pharmaceuticals Inc.
- American Biodyne
- ArQule Inc.
- Assured Health Systems
- Bone Measurement Institute
- BritCair Ltd.
- cCAM Biotherapeutics Ltd.
- Cubist Pharmaceuticals Inc.
- GlycoFi Inc.
- Hangzhou MSD Pharmaceutical Co. Ltd.
- Idenix Pharmaceuticals Inc.
- Inspire Pharmaceuticals Inc.
- IOmet Pharma Ltd.
- Merck BioVentures
- Merck Consumer Healthcare Group
- Merck Frosst Canada Inc.
- Merck Genome Research Institute
- Merck Human Health Division
- Merck Research Laboratories
- Merck Sharp & Dohme Ltd.
- Merck Specialty Chemicals Group
- Merck Vaccine Division
- Merck-Supera Farma JV
- MSD Consumer Care Inc.
- MSD India
- MSD KK
- NovaCardia Inc.
- Oncoethix SA
- Peloton Therapeutics Inc.
- Rigontec GMBH
- Rosetta Inpharmatics LLC
-
Schering-Plough Corp.
- Canji Inc.
- DNAX Research Institute
- Essex Chemie AG
- Integrated Therapeutics Group Inc.
- Key Pharmaceuticals Inc.
- NeoGenesis Pharmaceuticals Inc.
- Organon NV
- Schering Canada
- Schering Corp.
- Schering Laboratories
- Schering-Plough (Brinny) Co.
- Schering-Plough Healthcare Products Inc.
- Schering-Plough Ltd.
- Schering-Plough Pharmaceuticals
- Schering-Plough Research Institute
- Scholl International
- Scholl US Division
- Shanghai Schering-Plough Pharmaceutical Co. Ltd.
- Warrick Pharmaceuticals
- Sibia Neurosciences Inc.
- SmartCells Inc.
- SMSD (Shanghai) Ltd.
- SysteMed Inc.
- Tilos Therapeutics Inc.
- Viralytics Ltd.
- West Point Pharma
- Senior Management
-
Kenneth C Frazier, CEO
Robert M Davis, EVP, CFO
Frank Clyburn, EVP, Chief Commercial Officer - Contact Info
-
Merck & Co. Inc.
Phone: (908) 740-4000
2000 Galloping Hill Rd.
Kenilworth, NJ 07033
USA